Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Mark Brody"'
Autor:
Mark Brody, Marc Agronin, Brad J. Herskowitz, Susan Y. Bookheimer, Gary W. Small, Benjamin Hitchinson, Kevin Ramdas, Tyler Wishard, Katalina Fernández McInerney, Bruno Vellas, Felipe Sierra, Zhijie Jiang, Lisa Mcclain‐Moss, Carmen Perez, Ana Fuquay, Savannah Rodriguez, Joshua M. Hare, Anthony A. Oliva, Bernard Baumel
Publikováno v:
Alzheimer's & Dementia. 19:261-273
We hypothesized that Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapeutic candidate for Alzheimer's disease (AD), is safe and potentially disease-modifying via pleiotropic mechanisms of action.We prospectively tested the predictions th
Autor:
Kevin N. Ramdas, Mark Brody, Brad Herskowitz, Marc Agronin, Jorge G Ruiz, Ana Fuquay, Savannah Rodriguez, Danial Mehranfard, Lisa McClain‐Moss, Dan Gincel, Joshua M. Hare, Anthony A. Oliva
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Carl Chiang, Jacquelynn Copeland, Vanessa Raymont, Peter Connelly, Reto Kressig, Guy G. Potter, Daniel K. Burns, Stephen Pearson, Manish Saxena, Ann M. Saunders, Debra Fleischman, DeRen Huang, Thomas Leyhe, Gabriel Leger, Gigi Lefebvre, Mardik Donikyan, Natalie Denburg, Alex Knopman, Nancy Voight, James Burke, Philip Moore, James R. Burke, Margaret Newson, Stephen Haneline, Adam J. Schwarz, George Demakis, Joseph Butchart, Robert Mitchell, Mark Leibowitz, Michael Woodward, Robert Alexander, Concetta Forchetti, Emiliangelo Ratti, Andreas U. Monsch, Lon S. Schneider, Aaron Ritter, Joscelyn Agron-Figueroa, Fraser Inglis, Craig Curtis, Judith Neugroschl, Geraint Price, Mark Brody, Clark Johnson, Clive Ballard, Stephen Thein, Meredith Culp, Kristine Yaffe, Ahad Sabet, Walter Braude, Gregory Kirk, David Krefetz, Rupert Noad, Omid Omidvar, John Sass, Brenda L. Plassman, James Bergthold, Arne Klostermann, Haydn Till, Aaron Ellenbogen, Patrick Harrigan, Heinz-Peter Herbst, Joseph Kass, Lorna Wallace, Jennifer Robinson, Elliot Henderson, Felicia Goldstein, Christopher McWilliam, R. Clarnette, Jerry Halsten, Dan Rujescu, Silvana Micallef, Nestor Galvez-Jimenez, Jeffrey Ross, Dag Aarsland, Hugh Miller, Theresa Campbell, Jingtao Wu, Allan Levey, Liebhild Stratmann, Rosalyn Lai, Agnes Flöel, Richard Shingleton, Steve Higham, Pierre N. Tariot, Esteban Olivera, Sandra Carusa, Amanda Olley, Ricky Mofsen, Kathryn Goozee, Kara Lyons, Richard J. Brown, Marwan N. Sabbagh, Virginia De Sanctis, Jerome Goldstein, Hamid R. Sohrabi, Lefkos T. Middleton, Eugen Schlegel, Donna Munic-Miller, Sylvia Robinson, David Watson, Oda Ackermann, Ralph Votolato, Peter Bailey, Paul Massman, Daniel Gruener, Robert Perneczky, Frederick Schaerf, Craig W. Ritchie, Scott Losk, Christina Zimmerman, Mario Parra, Jill Crusey, Edward Zamrini, Christine Belden, Thomas Arnold, Alexander White, Linda Rice, Elizabeth Coulthard, Jane Martin, Anne Koplin, Rebecca Evans, Janet O'Neil, Oliver Peters, Raj Shah, Marshall Nash, Ronald Bradley, Kathleen A. Welsh-Bohmer, Howard Hassman, Scott Barton, Robert Cohen, Robert Stephenson, Jacobo Mintzer, Michael W. Lutz, Wendy Bond, Rachelle S. Doody, Ronald Hofner, Laura Samson
Publikováno v:
The Lancet Neurology. 20:537-547
Background: The identification of people at risk of cognitive impairment is essential for improving recruitment in secondary prevention trials of Alzheimer's disease. We aimed to test and qualify a biomarker risk assignment algorithm (BRAA) to identi
Autor:
Anthony A. Oliva, Mark Brody, Marc Agronin, Brad Herskowitz, Susan Y Bookheimer, Ben Hitchinson, Kevin Ramdas, Tyler Wishard, Lisa McClain‐Moss, Liliana A. Diaz, Keyvan Yousefi, Carmen Perez, Ana Fuquay, Savannah Rodriguez, Joshua M. Hare, Bernard Baumel
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Ricardo Castaneda, Marc E. Agronin, Anthony A. Oliva, Joshua M. Hare, Mark Brody, Carmen Perez, Lisa McClain-Moss, Ben Hitchinson, Ana Fuquay, Geoff Green, Kevin Ramdas, Brad Herskowitz, Susan Y. Bookheimer, Andrea Pena, Johanna Delucca, Liliana A. Diaz, Savannah Rodriguez, Bernard Baumel
Publikováno v:
Alzheimer's & Dementia. 16
Autor:
Audrey Medina, Cristine Chisholm, Jonathan Landman, Joshua M. Hare, Mark Brody, Anthony A. Oliva, Tequesta Alston, Lisa McClain-Moss, Carmen Perez, Benard Baumel
Publikováno v:
Alzheimer's & Dementia. 14
Autor:
Christopher H. van Dyck, William Cho, Mark Brody, Deborah Mortensen, Robert Paul, Michael Ward, Reina N. Fuji, Lee A. Honigberg, David Clayton, Michel Friesenhahn, Craig Curtis, Sharon Cohen, Christina Rabe, Flavia Brunstein, Carole Ho, Jeffrey L. Cummings, Angelica Quartino
Publikováno v:
Neurology
ObjectiveTo evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD).MethodsIn this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Pa
Autor:
Joshua M. Hare, Bernard Baumel, Lisa McClain-Moss, Ricardo Castaneda, Marc E. Agronin, Amy Drouillard, Jonathan Landman, Anthony A. Oliva, Carmen Perez, Mark Brody, Tequesta Alston, Andrea Pena, Suzanne L. Page, Susan Y. Bookheimer
Publikováno v:
Alzheimer's & Dementia. 15:P586-P586
Autor:
Mark Brody, Sheila Ashdown
“This thorough guide to techniques, tools, and materials is filled with expert tips and tricks. The detailed project instructions will inspire you to make your own mosaicked mark on the landscape.” —Lorene Edwards Forkner, author of Handmade Ga
Autor:
Ming Lu, Jianing Di, Anna Shadman, H. Robert Brashear, Richard Margolin, Gerald Novak, John L. Werth, Mark Brody, Kevin Booth, Enchi Liu
Publikováno v:
Journal of Alzheimer's disease : JAD. 54(4)
Background Bapineuzumab, a humanized monoclonal antibody, targets amyloid-β (Aβ1-40/1 -42) that is believed to play a key role in the pathogenesis of Alzheimer disease (AD). Objectives To assess the effects of monthly subcutaneous (SC) bapineuzumab